S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Europe bans Russian diesel, other oil products over Ukraine
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Route to Super Bowl dangerous for Mexico's avocado haulers
Biden's State of the Union to tout policy wins on economy
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
How will EU ban and West's price cap on Russian diesel work?
Evacuations urged in Ohio town as train wreck smolders
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
'Knock at the Cabin' knocks off 'Avatar' at the box office
NASDAQ:INM

InMed Pharmaceuticals - INM Stock Forecast, Price & News

$2.20
+0.12 (+5.77%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.85
$2.24
50-Day Range
$1.32
$2.74
52-Week Range
$1.23
$35.50
Volume
477,684 shs
Average Volume
866,755 shs
Market Capitalization
$2.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
INM stock logo

About InMed Pharmaceuticals (NASDAQ:INM) Stock

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INM Stock News Headlines

Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
InMed Announces Results of 2022 Annual General Meeting
InMed Provides Update on Management Changes
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
InMed Pharmaceuticals Shares Drop After Monday Rise
InMed adds 63% on rising volume after private placement
S&P 500 Rises 1%, InMed Pharmaceuticals Shares Spike Higher
InMed Pharmaceuticals Inc. (INM)
Stocks in play: InMed Pharmaceuticals Inc
See More Headlines
Receive INM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InMed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

INM Company Calendar

Last Earnings
11/11/2022
Today
2/05/2023
Next Earnings (Estimated)
2/13/2023
Fiscal Year End
6/30/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:INM
Fax
N/A
Employees
12
Year Founded
N/A

Profitability

Net Income
$-18,600,000.00
Net Margins
-1,356.41%
Pretax Margin
-1,355.85%

Debt

Sales & Book Value

Annual Sales
$1.09 million
Book Value
$13.95 per share

Miscellaneous

Free Float
915,000
Market Cap
$2.07 million
Optionable
Not Optionable
Beta
-0.24

Key Executives

  • Mr. Eric A. Adams B.S. Chem. (Age 60)
    M.I.B., Pres, CEO & Director
    Comp: $363.17k
  • Ms. Alexandra Diane-Janet Mancini M.Sc. (Age 70)
    Sr. VP of Clinical & Regulatory Affairs
    Comp: $261.03k
  • Dr. Eric Chih-Hsien Hsu (Age 53)
    Sr. VP of Preclinical R&D
    Comp: $253.46k
  • Dr. Sazzad Hossain M.Sc. (Age 65)
    Ph.D., Co-Founder
  • Mr. Jonathan R. Tegge (Age 33)
    Interim Chief Financial Officer
  • Mr. Michael Woudenberg P.Eng. (Age 54)
    Chief Operating Officer
  • Ms. Sarah Li CPA
    CGA, VP of Accounting & Controller
  • Colin Clancy
    Sr. Director of Investor Relations
  • Mr. Jerry P. Griffin
    VP of Sales & Marketing
  • Dr. Shane A. Johnson Ph.D.
    Sr. VP & GM of BayMedica













INM Stock - Frequently Asked Questions

Should I buy or sell InMed Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for InMed Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" INM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INM, but not buy additional shares or sell existing shares.
View INM analyst ratings
or view top-rated stocks.

How have INM shares performed in 2023?

InMed Pharmaceuticals' stock was trading at $2.02 at the beginning of the year. Since then, INM shares have increased by 8.9% and is now trading at $2.20.
View the best growth stocks for 2023 here
.

When is InMed Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 13th 2023.
View our INM earnings forecast
.

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc. (NASDAQ:INM) issued its earnings results on Friday, November, 11th. The company reported ($4.06) EPS for the quarter, beating analysts' consensus estimates of ($4.25) by $0.19. The business earned $0.32 million during the quarter. InMed Pharmaceuticals had a negative net margin of 1,356.41% and a negative trailing twelve-month return on equity of 169.59%.

When did InMed Pharmaceuticals' stock split?

Shares of InMed Pharmaceuticals reverse split on Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What is InMed Pharmaceuticals' stock symbol?

InMed Pharmaceuticals trades on the NASDAQ under the ticker symbol "INM."

How do I buy shares of InMed Pharmaceuticals?

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InMed Pharmaceuticals' stock price today?

One share of INM stock can currently be purchased for approximately $2.20.

How much money does InMed Pharmaceuticals make?

InMed Pharmaceuticals (NASDAQ:INM) has a market capitalization of $2.07 million and generates $1.09 million in revenue each year. The company earns $-18,600,000.00 in net income (profit) each year or ($30.98) on an earnings per share basis.

How can I contact InMed Pharmaceuticals?

The official website for the company is www.inmedpharma.com. The company can be reached via phone at 604-669-7207 or via email at info@inmedpharma.com.

This page (NASDAQ:INM) was last updated on 2/5/2023 by MarketBeat.com Staff